林业发展局批准将Lumakras和Vectibix结合对特定直肠癌病人进行新治疗,延长存活期。 FDA approves new treatment combining Lumakras and Vectibix for specific colorectal cancer patients, extending survival.

美国食品和药物管理局批准使用Lumakras (sotorasib) 和Vectibix (panitumumab) 联合治疗已经接受某些化疗的成年KRAS G12C突变转移性结直肠癌患者. The FDA has approved the combination of Lumakras (sotorasib) and Vectibix (panitumumab) to treat adults with KRAS G12C-mutated metastatic colorectal cancer who have already received certain chemotherapies. 这一新治疗方法大大改善了无进展生存,将其延长至5.6个月,而标准护理为2个月。 This new treatment significantly improves progression-free survival, extending it to 5.6 months compared to 2 months with standard care. 核准的依据是《法典》300研究报告。 The approval is based on the CodeBreaK 300 study. 常见副作用包括皮疹、皮肤干燥、腹泻和疲劳。 Common side effects include rash, dry skin, diarrhea, and fatigue.